Inyección de acción prolongada de RISPERDAL® CONSTA® (risperidona)

Comprendiendo la esquizofrenia
Tratamiento de la esquizofrenia
Importancia de mantenerse en el tratamiento
RISPERDAL CONSTA: una alternativa diferente
El equipo de profesionales de la salud mental
Reconocer las señales de la recaída
Tratamiento sicosocial, rehabilitación y apoyo
Cuidarse a sí mismo
Centro de noticias
Recursos
Para pacientes
Also in English
Información completa de prescripción en los EE.UU.
Mapa del sitio
Recursos a nivel mundial
Informe a un amigo(a)
Política de privacidad
Aviso legal
Versión para imprimir
 Tamaño del texto:  S | M |  L
 
 
 


Para los proveedores de cuidado

El factor más importante que influye al paciente con esquizofrenia a que continúe o no con los medicamentos es la familia y el apoyo social.

La esquizofrenia no afecta sólo al individuo, sino a la familia entera. Frecuentemente, un miembro de la familia asume el cuidado del ser querido que padece de esquizofrenia. El papel que usted desempeña en dar apoyo y ánimo al ser querido tiene una importancia vital para su mejoría. Por muy devastador que un diagnóstico de esquizofrenia pueda parecer, hay esperanza. Las investigaciones demuestran que los pacientes que cuentan con el apoyo de un proveedor de cuidado suelen tener menos episodios de recaídas y una mejoría más trascendental. Con tratamiento, orientación y apoyo, muchas personas con esquizofrenia pueden desarrollar la habilidad necesaria para tener vidas plenas, productivas e independientes.

La información en esta sección está diseñada para ayudarle a usted, el proveedor de cuidado, a brindar el mejor cuidado posible a su amigo o familiar con esquizofrenia.

<Volver arriba>

 

RISPERDAL® CONSTA® (risperidone) is used for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL® CONSTA®

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL® CONSTA® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL® CONSTA® and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL® CONSTA® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL® CONSTA® and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL® CONSTA®. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL® CONSTA® and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

01CS1054




Some people taking RISPERDAL® CONSTA® may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect can be reduced or it may go away over time.

RISPERDAL® CONSTA® may affect your alertness or driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® CONSTA® should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Inform your healthcare professional if you become pregnant or intend to become pregnant during therapy with RISPERDAL® CONSTA®. Caution should be exercised when RISPERDAL® CONSTA® is administered to a nursing woman.

RISPERDAL® CONSTA® may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

Some medications interact with RISPERDAL® CONSTA®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while on RISPERDAL® CONSTA®.

In a study of people taking RISPERDAL® CONSTA®, the most common side effects in the treatment of schizophrenia were headache, tremors, dizziness, restlessness, tiredness, constipation, indigestion, sleepiness, weight gain, pain in the limbs, and dry mouth.

If you have any questions about RISPERDAL® CONSTA® or your therapy, talk with your doctor.

For more information, read the Important Product Information by clicking here.



Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Página principal   Janssen.com   Mapa del sitio    Contáctenos   

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003 – 2008. Este sitio está publicado por Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., único responsable del contenido. Este sitio está dirigido a residentes de los Estados Unidos.
Esta página fue actualizada por última vez el: